Results 211 to 220 of about 116,902 (309)

PARP inhibitors induce a senescence phenotype in non‐small cell lung carcinoma cell lines

FEBS Open Bio, Volume 16, Issue 7, Page 1370-1386, July 2026.
Talazoparib is the most potent inducer of senescence among different PARP1 inhibitors in human NSCLC cells. In the absence of PARP, no senescence phenotype was observed, demonstrating that PARP1 is necessary for the induction of senescence by this inhibitor.
Camille Huart, Manon Van den Abbeel, Christoph Schifflers, Karim Bouhjar, Andrea Scarmelotto, Alexis Khelfi, Anne‐Catherine Wera, Carine Michiels   +7 more
wiley   +1 more source

Post-booster longitudinal plasma proteomic changes following BNT162b2 COVID-19 vaccination in Qatar. [PDF]

Front Immunol
Bentebbal S, Zaqout A, Meqbel B, Bensmail I, Aldushain A, de la Fuente A, Thomas R, Naik A, Shaath H, Al-Akl NS, Adam A, Moussa HYA, Shin KC, Taha RZ, Abukhattab M, Al-Maslamani MA, Alajez NM, Arredouani A, Park Y, Abdulla SA, El-Agnaf OMA, Abdesselem HB, Omrani AS, Decock J.   +23 more
europepmc   +1 more source

The Chemical Regulatory Landscape of Biomolecular Condensates

Aggregate, Volume 7, Issue 7, July 2026.
Chemical regulation of biomolecular phase separation offers a unique opportunity to bridge molecular‐level chemistry with emergent cellular organization. Chemically informed strategies for controlling condensate condensates through chemically tractable parameters such as interaction valency, solvent quality, and molecular crowding provides a unifying ...
Di Liu, Xin Zhang
wiley   +1 more source

A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. [PDF]

Clin Cancer Res
Huffman BM, Diossy M, Yurgelun MB, Horick N, Li YY, Crowdis J, Nguyen H, Parmar K, Kochupurakkal BS, Vonk L, Lam H, Ramsey K, Andrews E, Loeb SC, Culnane L, Biller LH, Bullock AJ, Enzinger A, Giannakis M, Jackson NA, Ng K, Nowak JA, Patel AK, Perez KJ, Rattani A, Rubinson DA, Schlechter BL, Singh H, Cai M, Raghavan S, Clark JW, Peters ML, Weipert CM, Wolpin BM, D'Andrea AD, Shapiro GI, Aguirre AJ, Szallasi Z, Cleary JM.   +38 more
europepmc   +1 more source

Death by PARP [PDF]

Genome Biology, 2002
openaire   +1 more source

Nicotinamide Reverses the Warburg Effect in CHO Cell Culture

Biotechnology and Bioengineering, Volume 123, Issue 7, Page 1902-1915, July 2026.
ABSTRACT The Warburg effect, the preferential conversion of glucose‐derived pyruvat to lactate despite available oxygen, is a key feature of Chinese hamster ovary (CHO) cell culture. Lactate accumulation in recombinant protein‐producing cell culture is an inefficient usage of glucose, as well as being deleterious to cells.
James Morrissey, Ayca Cankorur‐Cetinkaya, Luigi Grassi, Annie J. Harwood‐Stamper, Jonathan Welsh, Ryte Poskute, Kasia Kozakowska‐McDonnell, Cleo Kontoravdi   +7 more
wiley   +1 more source

PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges. [PDF]

Cells
Matsuoka T, Akamatsu S, Ong CJ, Gleave ME, Wang Y.   +4 more
europepmc   +1 more source

Patient‐reported outcomes in castration‐resistant prostate cancer with bone metastases treated with radium‐223 with or without olaparib

Cancer, Volume 132, Issue 13, 1 July 2026.
Abstract Background The combination of olaparib plus radium‐223 improved progression‐free survival in patients with metastatic castration‐resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient‐reported outcome (PRO) analysis of this trial is reported.
Rana R. McKay, Wanling Xie, Archana Ajmera, Arlene Araneta, Edmund Folefac, Arif Hussain, Christos E. Kyriakopoulos, Adam Olson, Mamta Parikh, Rahul Parikh, Biren Saraiya, Geoffrey I. Shapiro   +11 more
wiley   +1 more source

ARGLU1 in Glioma: A Novel Potential Regulator of Splicing, DNA Repair, and Therapeutic Resistance. [PDF]

Cells
Wu X, Yi D, Tie D, Du M, Wang M, Yu Z, Xu Y.   +6 more
europepmc   +1 more source

Is a Clinical Trial With a Non‐Bioequivalent Batch Necessary? The Critical Role of Intrasubject Variability in Olaparib Formulation Bridging by PBPK

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 203-213, July 2026.
Although physiologically based pharmacokinetic (PBPK) modeling is increasingly being used to support oral drug formulation bridging, the acceptance by regulatory agencies is low. One of the primary concerns is the absence of clinical pharmacokinetic (PK) data from a non‐bioequivalent (non‐BE) batch during model validation.
Jin Dong, Andrea Moir, Xavier Pepin, Elizabeth Lowe, Sandy Hopkins, Weifeng Tang, Diansong Zhou   +6 more
wiley   +1 more source